SLCTR_2020_023
A clinical study using Evenamide (orally taken new drug with out masking its strenghth) to determine its safety, tolerability and efficacy in patients with treatment resistant schizophrenia, not befitting adequately from their current antipsychotic medication
A pilot, open-label, rater-blinded, randomized, parallel-group, multi-center study to evaluate the safety, tolerability and preliminary efficacy of three add-on fixed doses of evenamide in patients with treatment-resistant schizophrenia (TRS) not responding adequately to their stable, therapeutically active dose of a single antipsychotic medication
Dr Ravi Anand·Phase 2·Sri Lanka Clinical Trials RegistryCompleted
Study focus
- Disease/Condition
- schizophrenia
- Study type
- Interventional
Sponsor & location
- Primary sponsor
- Dr Ravi Anand
- Location
- India
Timeline & enrollment
- Phase
- Phase 2
- Start date
- Feb 12, 2021
- End date
- N/A
ICD-10 classifications
SchizophreniaSimple schizophreniaSchizophrenia, unspecifiedOther schizophreniaParanoid schizophrenia
Data source
- Registry
- Sri Lanka Clinical Trials Registry
- Trial ID
- SLCTR_2020_023
- Type
- Non-Device Trial
About this record
Access comprehensive clinical trial information for SLCTR_2020_023 through Pure Global AI's free database. This Phase 2 trial is sponsored by Dr Ravi Anand and is currently Completed. The study focuses on schizophrenia.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to Sri Lanka Clinical Trials Registry data, helping medical device and pharmaceutical companies navigate clinical research efficiently.